AstraZeneca has been urging sports fans to “Get Body Checked Against Cancer” in a campaign launched in collaboration with the ...
AstraZeneca’s senior director in oncology data science outlined how the company uses AI for drug discovery at a recent talk.
4h
Investor's Business Daily on MSNAstraZeneca ADR Scores Relative Strength Rating Upgrade; Hits Key ThresholdAstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.
1d
Investor's Business Daily on MSNAstraZeneca Stock Nears Buy Point After Long Run In Declining MarketAstraZeneca is Thursday's pick for IBD 50 Growth Stocks To Watch as the biopharmaceutical name is holding up relatively well ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...
The AstraZeneca PLC ADR AZN rose 1.79% to $75.57 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...
AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...
UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...
Ionis Pharmaceuticals (IONS) announced that Ionis and AstraZeneca’s (AZN) WAINZUA eplontersen has been approved in the European Union EU for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results